Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoPHBBF 90 EV-to-FCF is 257.97 as of Jul. 26, 2026, which is 166% above its 10-year median of 96.81. GuruFocus rates PHBBF with a GF Score™ of 90/100 and a GF Value™ of $1.67. The stock has 9 warning signs investors should review. Among 340 Biotechnology companies, Pharmaron Beijing Co ranks worse than 95% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharmaron Beijing Co's Enterprise Value is $10,195 Mil.
Pharmaron Beijing Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $40 Mil. Therefore, Pharmaron Beijing Co's EV-to-FCF for today is 257.97.
The historical rank and industry rank for Pharmaron Beijing Co's EV-to-FCF or its related term are showing as below:
PHBBF'
s EV-to-FCF Range Over the Past 10 Years
Min: -3479.85 Med: 96.81 Max: 1353.73
Current: 246.5
During the past 12 years, the highest EV-to-FCF of Pharmaron Beijing Co was 1353.73. The lowest was -3479.85. And the median was 96.81.
PHBBF's EV-to-FCF is ranked worse than 95% of 340
companies
in the Biotechnology industry
Industry Median: 14.79
vs PHBBF: 246.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharmaron Beijing Co (OTCPK:PHBBF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharmaron Beijing Co's PE Ratio (TTM) for today is calculated as:
Pharmaron Beijing Co's share price for today is $1.93.
Pharmaron Beijing Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.135.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pharmaron Beijing Co EV-to-FCF Related Terms
Pharmaron Beijing Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharmaron Beijing Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's EV-to-FCF falls into.
Pharmaron Beijing Co's current Enterprise Value is $10,195 Mil.
Pharmaron Beijing Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (PHBBF) has a EV-to-FCF of 257.97 as of Jul. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharmaron Beijing Co and its competitors. This is 166% above median its historical median of 96.81. According to the industry distribution chart, Pharmaron Beijing Co ranks #323 out of 340 companies in the Biotechnology industry, placing it in the top 95%.
Is Pharmaron Beijing Co's EV-to-FCF too high?
Pharmaron Beijing Co's current EV-to-FCF of 257.97 is 166% above median its 10-year median of 96.81. The Biotechnology industry median EV-to-FCF is 14.79. Pharmaron Beijing Co's value of 257.97 is 1644.2% above this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #323 out of 340 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #323 out of 340 companies for EV-to-FCF. This places Pharmaron Beijing Co in the lower half of its industry. The industry median EV-to-FCF is 14.79. Pharmaron Beijing Co's value of 257.97 is 1644.2% above this benchmark. While the company's 10-year median is 96.81 vs. the industry median of 14.79, Pharmaron Beijing Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.79, based on 340 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current EV-to-FCF of 257.97 is 1644.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current EV-to-FCF is 257.97, which is 166% above median its own 10-year median of 96.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current EV-to-FCF of 257.97. The stock's GF Value™ is $1.67, compared to a current price of $1.93 — trading 15.6% above its estimated fair value. The current EV-to-FCF is 257.97, which is 166% above median its 10-year median of 96.81 and 1644.2% above the Biotechnology industry median of 14.79. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current EV-to-FCF is 257.97 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of $1.93 is trading 15.6% above its estimated GF Value™ of $1.67.
Key valuation signals for PHBBF:
EV-to-FCF: 257.97 (166% above median its 10-year median of 96.81)
GF Value™: $1.67 vs. price of $1.93 (15.6% above fair value)
Industry Position: 1644.2% above the Biotechnology median (#323 of 340)
No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for PHBBF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBBF has been successfully added to your 
